GENFIT
GNFT | PA
Overview
Corporate Details
- ISIN(s):
- FR0004163111 (+2 more)
- LEI:
- 969500XPWN2DMZQA5X73
- Country:
- France
- Address:
- 885 AVENUE EUGENE AVINEE, 59120 LOOS
- Website:
- https://www.genfit.com
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
GENFIT is a late-stage biopharmaceutical company dedicated to developing innovative therapeutic and diagnostic solutions for patients with rare and life-threatening liver diseases. The company leverages its expertise in drug discovery and late-stage development to advance a diversified pipeline. Its primary therapeutic focus is Acute-on-Chronic Liver Failure (ACLF), with multiple assets targeting differentiated mechanisms of action. The R&D pipeline also includes programs for other severe conditions such as Cholangiocarcinoma (CCA) and Urea Cycle Disorders (UCD). GENFIT's development capabilities are validated by its successful pivotal Phase 3 trial for elafibranor in Primary Biliary Cholangitis (PBC), an asset discovered by the company and licensed to a partner for commercialization.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for GENFIT.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-17 20:30 |
Post-Annual General Meeting Information
GENFIT : Résultats de l’Assemblée Générale Mixte du 17 juin 2025
|
French | 140.4 KB | |
| 2025-06-17 20:30 |
Post-Annual General Meeting Information
GENFIT: June 17, 2025 Combined Shareholders Meeting Results
|
English | 140.0 KB | |
| 2025-05-22 22:10 |
Quarterly Report
GENFIT Reports First Quarter 2025 Financial Information
|
English | 163.4 KB | |
| 2025-05-22 22:10 |
Earnings Release
GENFIT : Information financière du premier trimestre 2025
|
French | 146.7 KB | |
| 2025-05-20 22:10 |
Regulatory News Service
GENFIT to receive a €26.5 million milestone payment following the approval of p…
|
English | 143.6 KB | |
| 2025-05-20 22:10 |
Regulatory News Service
GENFIT va recevoir un paiement d’étape de 26,5 millions d’euros à la suite de l…
|
French | 137.3 KB | |
| 2025-05-14 22:10 |
Environmental & Social Information
GENFIT: Publication of the 2025 Extra-Financial Performance Report (fiscal year…
|
English | 793.3 KB | |
| 2025-05-07 22:10 |
Pre-Annual General Meeting Information
GENFIT : Assemblée Générale Mixte du 17 juin 2025 — modalités de mise à disposi…
|
French | 129.1 KB | |
| 2025-05-07 22:10 |
Pre-Annual General Meeting Information
GENFIT Annual Combined General Meeting of June 17, 2025 — Availability of Prepa…
|
English | 135.6 KB | |
| 2025-05-05 07:30 |
Environmental & Social Information
GENFIT présentera ses dernières avancées dans l'ACLF à l’EASL Congress 2025
|
French | 228.8 KB | |
| 2025-05-05 07:30 |
Regulatory News Service
GENFIT to Present Latest ACLF Research at EASL Congress 2025
|
English | 220.7 KB | |
| 2025-04-29 21:10 |
Registration Form
GENFIT : Mise à disposition du Document d’Enregistrement Universel 2024 et du R…
|
French | 516.5 KB | |
| 2025-04-29 21:10 |
Report Publication Announcement
GENFIT Announces Publication of the 2024 Universal Registration Document and th…
|
English | 648.6 KB | |
| 2025-04-29 12:14 |
Annual Report (ESEF)
Document d'Enregistrement Universel 2024
|
French | 10.4 MB | |
| 2025-04-28 22:10 |
Regulatory News Service
GENFIT : les données positives de la Phase 2 évaluant elafibranor dans la Chola…
|
French | 181.9 KB |
Automate Your Workflow. Get a real-time feed of all GENFIT filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for GENFIT via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-07-07 | N/A | Other | Buy | 5,300 | 19,488.10 EUR |
| 2023-07-06 | N/A | Other | Buy | 1,100 | 4,048.00 EUR |
| 2023-07-05 | N/A | Other | Buy | 10,000 | 37,061.00 EUR |
| 2023-07-03 | N/A | Other | Buy | 5,300 | 18,769.95 EUR |
